Veeva Systems: A Deep Value Investing Study

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?6/10

  A

  The ceiling is real but finite: Veeva is mainly deepening and enlarging an existing software/data pie in life sciences, not creating an entirely new market from scratch; the only recent increment that truly looks “newly created” is industry AI agents, and that piece is still in validation.

  Start by defining the pie. At its 2024 Investor Day, Veeva described the life sciences industry as “more than $2 trillion” in size with long-term growth of 6%+, and estimated its own serviceable addressable market (SAM) at “more than $20 billion,” with FY2025E penetration of about 14%. The report has already clearly marked this as a management estimate/forward-looking view, not a conclusion independently audited by a third party. This framing has two implications: first, the ceiling is indeed far above the current level (against a $20 billion+ SAM, FY2026 revenue of $3.195 billion still implies low penetration and a long runway); second, this is essentially about taking a higher share in an already existing, regulation-driven, inevitably digitizing industry, not opening a new category that no one previously needed. Demand for life sciences software comes largely from compliance. The U.S. FDA’s 21 CFR Part 11 requires audit trails, validation, and record integrity for regulated electronic records and electronic signatures. That “operating infrastructure” nature means the pie is stable and mission-critical, but it also means the pie already exists and Veeva is penetrating an installed market.

  The best evidence that Veeva is “expanding an existing pie” is the share migration away from CRM within its own mix. CRM was Veeva’s founding product, accounting for about 75% of revenue in 2015, about 20% in 2025, and an expected roughly 10% in 2030. In other words, the main engine that doubled Veeva’s revenue over the past decade was not the creation of a new market out of thin air, but the sequential capture of adjacent pies such as clinical (Development Cloud), quality (Quality Cloud), and data (Data Cloud / Crossix), forming a suite that spans “R&D to commercialization.” With 1,552 customers at the end of FY2026 (under the report’s framing), this is a textbook path of expanding categories horizontally within the same industry, not creating demand.

  The only element with the flavor of “creating a new market” is industry AI agents, but it needs an honest haircut. In the FY2027 Q1 earnings release (as of 2026-04-30), the CEO explicitly repositioned the company from an “industry application company” to an “industry application + AI agent company”: Ostro, acquired in March, already provides compliant conversational AI for 50+ brands; Vault AI is planned to expand to all Vault applications in August; and Veeva Falcon, focused on “agentic labor,” is planned for early trials in November. This could indeed expand TAM from “selling software seats” to “selling work replaced by AI,” raising the theoretical ceiling. But it is still embedding AI into existing clinical/regulatory/safety workflows, with stronger competition (Salesforce launched Life Sciences Cloud + Agentforce in September 2025 to compete head-on). At this stage, it looks more like adding a new layer of seasoning to the old pie than a fully proven new market. I therefore include it in the “upside imagination,” not in the “already established ceiling.”

  The Baillie Gifford-style conclusion: Veeva’s ceiling is high enough to support long-term growth (the industry is not shrinking, penetration remains low, and compliance raises mission-critical demand), but the nature of growth is steady penetration rather than disruptive creation. It is an excellent student expanding an existing pie in a good industry. AI agents are the variable that could genuinely change the height of the ceiling, but they are also the most uncertain part today and must be tested by execution over the next 4–8 quarters.

  Jun 10, 2026
• QCan its revenue at least double over the next five years? Will growth mainly be driven by volume, price, or new businesses?5/10

  A

  A five-year revenue doubling (about 15% annual compound growth) is an achievable but stretching target, not the base case; growth is mainly volume-driven: new customers, existing customers buying more Cloud modules, and AI-driven expansion in seats/usage. Price is secondary, and pure new business (AI agents) is an upside option.

  Use realized facts to set the benchmark. Over the past five years, Veeva’s revenue grew from $1.465 billion in FY2021 to $3.195 billion in FY2026, slightly more than doubling over five years, at a compound rate of about 17%. But growth is naturally slowing: FY2027 full-year guidance (updated in the earnings release as of 2026-04-30) calls for total revenue of $3.635–$3.645 billion, only +14% versus FY2026’s $3.195 billion; FY2027 Q1 total revenue was $882.9 million, +16% year over year, and subscription revenue was $730.2 million, +15%. Doubling in five years requires roughly 15% annual compound growth without deceleration. Current subscription growth is already 15%, and the larger base creates downward pressure. So “at least doubling” is closer to the report’s neutral case (its 10% Owner Earnings growth assumption for the first five years is conservative, but 14–15% revenue growth to double sits at the neutral-to-optimistic boundary), not a lower bound one can underwrite blindly.

  Breaking growth into “volume, price, and new business,” the evidence points to volume as the overwhelming driver:

  • Volume (new customers + upsell to existing customers) is the main engine. Veeva is a suite penetration model, with incremental growth coming from two sources: serving more customers (1,552 at the end of FY2026, under the report’s framing), and moving existing customers from 1 Cloud to multiple Clouds. The clearest volume evidence is the Vault CRM replacement migration. In FY2027 Q1, Veeva added 27 Vault CRM customers in one quarter, already had 150+ live, had 10 of the top 20 biopharma companies globally committed by the end of FY2026, and management expected about 14 to commit over time. Enterprise wins in R&D and Quality Cloud (the same earnings release disclosed multiple large clinical/regulatory/safety deals) form the other main volume-growth line.

  • Price increases are a secondary, moderate helper. In the moat analysis, the report explicitly says Veeva “has pricing power, but not so strong that it can raise prices at will,” and the Checklist marks it as “pass, but not forceful.” Compliance binding and high switching costs do support renewals and moderate price increases, but Veeva is not a company whose growth is driven by large annual list-price increases. Price is more about preserving unit price and moving slightly with inflation than acting as the growth engine. The reverse risk deserves attention: the report cites the 10-K warning that large-customer consolidation may “reduce seat counts and compress unit price,” meaning both price and volume can be eroded by M&A.

  • New business (AI agents) is an upside option, not yet the main revenue driver. Ostro (acquired in March) already serves 50+ brands, Vault AI will be rolled out across all applications in August, and Veeva Falcon will enter early trials in November. This is a new monetization path from “selling seats” to “selling agentic labor”; if it works, it can materially accelerate volume growth because usage-based monetization has a higher ceiling. But today it remains in trial/early-adoption mode. It is a potential accelerator that can turn doubling from “stretching” into “easily achievable,” not a base-case engine already in the numbers.

  The Baillie Gifford-style conclusion: I would assign the probability of doubling in five years as positive but not highly certain. It depends on three things not breaking at the same time: Vault CRM migration, continued penetration of R&D/Quality Cloud, and AI usage starting to scale. The first two extend existing momentum (higher credibility), while the third is a new variable (still to be validated). The growth profile is healthy “volume-driven recurring revenue with strong inertia” (high subscription mix, with FY2026 subscription revenue of $2.684 billion accounting for the vast majority of total revenue), not fragile growth built on price increases or one-off projects.

  Jun 10, 2026
• QAfter five years, what will take over as the next growth engine? Does this “second curve” exist today?5/10

  A

  The second curve does exist today, and there is more than one. Deep penetration of R&D/Quality Cloud is the “near curve” already taking over; industry data (Data Cloud/Crossix) + AI agents (Veeva AI / Falcon) are the more distant curves. The difference is that the near curve has been validated, while the far curves are still in the monetization phase.

  Why a second curve is necessary: the original curve (commercial CRM) is actively shrinking as a share of the business. CRM was Veeva’s founding product, accounting for about 75% of revenue in 2015, about 20% in 2025, and an expected roughly 10% in 2030. That means the company has long been unable to rely on its first curve for growth. The doubling of revenue in recent years was itself the result of a second curve taking over. The question is therefore not “whether a second curve exists,” but “how mature each of the successor curves is.”

  The first and most mature near curve is R&D and Quality Solutions (clinical/regulatory/quality cloud). This is already the revenue core, not imagination. In FY2027 Q1 (as of 2026-04-30), R&D and Quality subscription revenue was $392.3 million, up from $329.4 million year over year (about +19%), making it the faster-growing of the two major segments; including professional services, the segment generated about $487.5 million in the quarter, already about 55% of total revenue. Under the report’s framing, R&D/Quality Solutions had 1,196 customers. It runs on the Vault platform (system-of-record attributes, high switching costs) and is a validated, sustainable successor engine. Baillie Gifford would count it as a real second curve, not a slide-deck story.

  The second, fastest-growing far curve is industry AI / agentic labor. This is the current narrative core. In the FY2027 Q1 earnings release, the CEO directly announced the company’s shift from an “industry application company” to an “industry application + AI agent company”: Ostro, acquired in March, already provides compliant conversational AI for 50+ brands; Vault AI will expand to all Vault applications in August; and Veeva Falcon (providing agentic labor for clinical/regulatory/safety) will begin early trials in November. Its appeal is that monetization can move from “seat subscriptions” to “work replaced,” raising the theoretical ceiling. But today it is still in trial/early-adoption mode. It is an existing but unproven curve, and competition is stronger (Salesforce launched Life Sciences Cloud + Agentforce in September 2025 to compete directly).

  The third, underlying data curve is Data Cloud / Crossix / Compass. Veeva is building data platforms around connected reference data, deep data, and transaction data. Once combined with CRM, marketing analytics, patient journeys, and target identification, these assets can strengthen stickiness and differentiation. On its own it may not be the largest engine, but it is the “fuel” for the AI curve. Without proprietary industry data, the moat around AI agents is thin.

  The honest risk side (which Baillie Gifford would not avoid): the report’s strongest bear argument is exactly that “the fattest dividend phase may have passed.” Traditional CRM is mature; new Data/AI opportunities are large, but competitors are stronger; further penetration in R&D/Quality Cloud will encounter longer sales cycles, stronger rivals, and greater organizational complexity. In other words, the second curve exists, but whether its slope can offset the maturation of the first curve still needs to be proven with facts over the next 3–5 years.

  The Baillie Gifford-style conclusion: Veeva is one of the few companies where the post-five-year successor engines can already be named today, and one of them is already contributing revenue. That is far better than companies whose second curve rests entirely on future imagination. I assign relatively high confidence to “the second curve exists and has partly materialized.” But the AI agent curve that will determine the real ten-year height is still early in monetization, making it a key item to watch rather than a banked conclusion.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  The core moat is a three-part combination of high switching costs deeply embedded in life sciences compliance workflows, suite coverage, and proprietary industry data. Over the next three to five years, my net judgment is “roughly stable, locally widening, with one real narrowing point”: Quality/Regulatory Cloud and AI+data are widening, while traditional commercial CRM faces a narrowing risk at the Vault migration gate, where competitors can pry at the account.

  First, the moat’s “past” and “present” must be separated. Historical indicators only prove that it used to be strong; forward-looking analysis must focus on the margin. Historically, Veeva’s strong moat has hard evidence: FY2026 subscription gross margin of 87% and total gross margin of 76% (under the report’s framing). That profit structure itself is the result of pricing power and switching costs. But high gross margin only proves the past effectiveness of the moat. Its future width depends on the marginal changes in the following four areas:

  Widening item 1 · Switching costs (strong and deepening). Veeva’s system-of-record products are embedded in documents, data, workflows, and compliance requirements. For customers subject to FDA 21 CFR Part 11 (electronic records/electronic signatures require audit trails, validation, and record integrity), replacement means revalidation, retraining, redesigned processes, and audit risk. The more Cloud modules a customer uses, the more painful it is to rip Veeva out. As penetration deepens, this moat should only widen.

  Widening item 2 · Data + AI compounding (widening directionally, but must be proven). FY2027 Q1 shows Veeva embedding Ostro’s compliant conversational AI (50+ brands), Vault AI (rolled out across all applications in August), and Veeva Falcon (early adoption in November) into existing workflows. If AI is fueled by proprietary industry data and deeply embedded in customer workflows, the moat can upgrade from “software lock-in” to “software + data + agent workflow lock-in,” making it theoretically wider. But this is a forward-looking 4–8-quarter marginal item and should not be treated as an already established moat.

  Narrowing item · The commercial CRM migration gate (real risk). This is the one place that deserves the most attention. Veeva’s legacy CRM still relies on the Salesforce platform and is migrating to its own Vault CRM. Legacy support is expected to continue only until 2029-12-31. The report cites the 10-K as saying directly that the migration could cause customer disruption, performance issues, delays, and even customer loss. Salesforce is no longer a partner but a direct competitor. In September 2025, it launched Life Sciences Cloud + Agentforce and claimed 70+ industry customers. In other words, every forced migration decision is a window for competitors to rebid the account. That is a real narrowing point where the moat is “reopened for price comparison” at a specific link. Management’s offsetting statement is that it still expects to retain at least 70% of biopharma CRM subscription revenue share by 2030, but the report correctly marks this as forward-looking, not a validated fact. Current migration progress provides positive marginal evidence: in FY2027 Q1, Veeva added 27 Vault CRM customers in one quarter and had 150+ live cumulatively; by the end of FY2026, 10 of the top 20 biopharma companies had committed, and about 14 were expected to commit over time. The migration is moving, but it is far from “the gate is closed and the risk is gone.”

  Neutral item · Network effects (already weak, not the main moat). The report judges network effects as “weak to moderate.” Veeva is not a two-sided platform; more customers do not directly make any single customer better off. The so-called network effect only appears through data accumulation and industry standardization, and it is not the primary moat. This should remain broadly unchanged over the next three to five years.

  The Baillie Gifford-style conclusion: Veeva’s moat is real and has already converted into high-gross-margin cash flow, with higher quality than most vertical SaaS companies. But it is not a monotonically widening story. Quality/Regulatory Cloud + data/AI are widening; the commercial CRM migration gate is narrowing. My net judgment is that the overall moat can largely hold and tilt slightly wider over the next three to five years, provided the Vault CRM migration does not lead to obvious share loss under Salesforce/Agentforce’s direct attack. Whether that gate opens or closes will decide the moat’s direction over the next three to five years.

  Jun 10, 2026
• QIf its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  It has fairly strong reinvention DNA, and this is not empty talk. Veeva is proving it through the real act of “actively dismantling the foundation of its founding business”: it is willing to overturn its short-term revenue structure for the long term. Its attitude toward mistakes and bad news is to write risks very plainly in the 10-K, which gives it high transparency, but it lacks a public postmortem on capital-allocation timing mistakes.

  Start with the implicit premise: when the core business is disrupted, does it have the DNA to reinvent itself? Veeva happens to provide a live example in progress. Its founding core (CRM) is being actively revolutionized by Veeva itself. CRM once accounted for about 75% of revenue (2015), now about 20%, and is expected to be about 10% in 2030. More importantly, Veeva did not simply sit on the Salesforce platform and harvest legacy profits. Despite the real risks of customer disruption and churn, it is rebuilding the entire CRM business onto its own Vault platform. This is classic self-disruption rather than passive waiting for decline. Instead of waiting for Salesforce or outsiders to eat away at CRM, it is moving CRM first onto a foundation it controls. In FY2027 Q1 (as of 2026-04-30), the more aggressive step was the CEO directly announcing the company’s shift from an “industry application company” to an “industry application + AI agent company,” alongside Ostro (acquired in March, already serving 50+ brands), Vault AI (rolled out across all applications in August), and Veeva Falcon (early adoption in November). While its own applications are still selling well, it is proactively rewriting the monetization narrative from “selling seats” to “selling agentic labor.” The ability to restructure while the core business is still cash-generative is the most convincing evidence of reinvention DNA, far stronger than companies that only shout “transformation” in PPT.

  Three structural supports underpin this reinvention DNA. First, financial strength gives it room to experiment: as of FY2027 Q1, cash plus short-term investments were about $7.31 billion (cash $1.897 billion + short-term investments $5.416 billion), with almost no interest-bearing debt, so reinvention will not be dragged down by the balance sheet. Second, it is a platform, not a single product: four major Clouds plus the Vault foundation allow it to move capabilities into adjacent workflows if one process is disrupted. Third, the founder has stayed in charge for the long term: CEO Peter Gassner has led since the IPO and beneficially owned about 9.4% (under the report’s framing, as of 2026-03-31), making him willing to undertake reconstruction today whose payoff may only appear five to ten years later.

  On mistakes and bad news, transparency is the strength and depth of postmortem is the weakness. The strength is that Veeva writes bad news into formal disclosures instead of beautifying it. The report repeatedly cites its 10-K disclosures about high reliance on reference selling, the possibility that large-customer consolidation may reduce seat counts and compress pricing, uncertainty around the Vault CRM migration, potential customer loss from disruption/performance problems/delays, and risks from data privacy and compliance. This is a company that dares to put the pain points in the risk factors, not one that hides them under “temporary fluctuations.”

  The weakness is that public review of capital-allocation errors is not deep enough. The most concrete example is buybacks: FY2026 repurchases were done at an average price of $224.43, and FY2027 Q1 saw another $221 million spent to repurchase about 1.3 million shares, while the current price is only about $167.68 (2026-06-09). This does not destroy the long-term thesis, but it shows that management is not especially disciplined on buyback timing. I have not seen a sufficiently clear public postmortem of this. In addition, high stock-based compensation is a structural cost: FY2026 SBC was $473 million, about 14.8% of revenue (under the report’s framing), and five-year share dilution was about 7.7%. It is disclosed transparently, but disclosure is not the same as solving the problem.

  The Baillie Gifford-style conclusion: Veeva has real reinvention DNA, evidenced by the Vault CRM migration and the AI agent shift, and its balance sheet and founder-led governance give it the capacity to do so. Its disclosure of bad news is relatively honest, especially around migration, customer concentration, and compliance risks. The deductions are not about concealment, but about the lack of deep public review of capital-allocation timing and the ongoing dilution from SBC. Overall: this is a company with strong self-renewal ability and high disclosure transparency, but not flawless capital-allocation discipline.

  Jun 10, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profits for five to ten years out?7/10

  A

  Management, especially the founder CEO, is one of the company’s strongest dimensions: the long-term view is clear, interests are deeply aligned with the company, and management has already used the real action of “actively sacrificing the short-term revenue structure to build a ten-year foundation” to prove its willingness to invest for the long run. The only reservations are dilution from large stock-based compensation and imperfect capital-allocation discipline in high-priced buybacks.

  Founder alignment: the hard data is solid. CEO and founder Peter Gassner beneficially owned about 15.638 million shares as of 2026-03-31, about 9.4% of common stock, while all directors and executives together owned about 10.6% (under the report’s framing). The incentive structure says even more about being “in the same boat” as shareholders: the CEO does not participate in the annual cash incentive plan, and since the IPO has received essentially no cash incentive beyond below-market base salary. Long-term incentives are mainly options with relatively high exercise prices and long vesting periods. This means his returns are almost entirely tied to long-term share price and enterprise value, not guaranteed cash bonuses. This is a textbook example of the “founder’s economic interest aligned with minority shareholders” that Baillie Gifford values most, with much purer alignment than professional managers who take large cash pay while holding little stock.

  Long-term view: backed by both institutions and actions. Institutionally, Veeva became a Public Benefit Corporation in 2021 and repeatedly writes “build a lasting company” into its operating philosophy. In governance, it converted all Class B shares into Class A in October 2023, and the 2026 proxy statement listed “single class of common stock” as a governance improvement. Voluntarily giving up the extra control of dual-class shares is a tangible goodwill gesture to outside shareholders, not the common founder pattern of clinging to control.

  “Is it willing to sacrifice current profits for five to ten years out?” Yes, with live evidence. The strongest evidence is the CRM self-revolution: despite the real risks of customer disruption and loss, Veeva is rebuilding the founding and still profitable CRM business from the Salesforce platform onto its own Vault platform (legacy support only through 2029-12-31); CRM’s revenue share actively fell from about 75% in 2015 to about 20% in 2025 and is expected to be about 10% in 2030. The newer step is that in FY2027 Q1 (as of 2026-04-30), the CEO announced the company’s repositioning as an “industry application + AI agent company,” and to support this acquired Ostro and launched Vault AI and Veeva Falcon. Investing proactively in a new platform while the application business still generates strong cash flow is an act of sacrificing near-term certainty for the long term, not a slogan. Notably, profitability is improving while it does this: FY2026 operating margin recovered to 28.7% (GAAP operating income $916 million) (under the report’s framing). This shows that long-term investment and current profitability have not become unbalanced. It is high-quality, disciplined long-termism.

  Two reservations must be stated honestly:

  First, stock-based compensation dilution is a real cost. FY2026 stock-based compensation was $473 million, about 14.8% of revenue (under the report’s framing), and ending shares rose from about 152.1 million in FY2021 to about 163.8 million in FY2026, a five-year dilution of about 7.7%. CEO option incentives create strong alignment, but company-wide SBC genuinely erodes per-share Owner Earnings. “Alignment of interests” and “shareholder dilution” are two sides that coexist at Veeva.

  Second, buyback timing discipline is not impressive. FY2026 buybacks were done at an average price of $224.43, and FY2027 Q1 saw another $221 million spent to repurchase about 1.3 million shares, while the current price is only about $167.68 (2026-06-09). Management is rational about “whether to buy back,” but not outstanding at “what price to buy back.” The report has already recorded capital allocation as “rational, but with reservations.”

  The Baillie Gifford-style conclusion: On the core Baillie Gifford aesthetic of “founder long-term vision + aligned interests + willingness to sacrifice short-term results for the long term,” Veeva is in the first tier. The founder owns a meaningful stake, cash incentives are extremely low, governance voluntarily gives ground to minority shareholders, and the CRM self-revolution is a real long-term action involving real money. The deductions are concentrated in “high SBC dilution + high-priced buyback discipline,” bringing it down from “perfect management” to “excellent but flawed.” These flaws would not make me lose trust in management, but they do require a cheaper purchase price to offset them.

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulation?6/10

  A

  If Veeva disappeared tomorrow, customers would miss it a great deal. It is operating infrastructure for regulated life sciences companies, not a nice-to-have efficiency tool; removing it would directly threaten compliance and business continuity. At the same time, its growth model is highly sustainable and does not depend on harming society or regulation. On the contrary, it is built on the positive job of helping customers meet regulation better. But one tension must be stated honestly: it increasingly depends on patient/prescription data, making data privacy a social and regulatory boundary it must manage for the long term.

  “How much would customers miss it?” Very high indispensability, with structural evidence. Veeva is not decorative SaaS; it is a system of record embedded across clinical, quality, regulatory, and commercial workflows. For customers subject to FDA 21 CFR Part 11 (electronic records/electronic signatures require audit trails, validation, permissions, and record integrity), Veeva carries capabilities necessary for compliance, not something merely “nice to have.” If it disappeared, customers would not face “a different login screen.” They would face a break in clinical trial documents, regulatory submissions, quality records, and the pharma commercialization compliance chain. Validation, training, and process redesign would all have to be redone, with real regulatory and audit risk during the transition. This is why the report judges switching costs as “strong” and business understandability as “4.5/5.” Customer density also supports indispensability: 1,552 customers served at the end of FY2026 (under the report’s framing), 10 of the top 20 biopharma companies globally committed to Vault CRM, and FY2027 Q1 already had 150+ Vault CRM customers live. The fact that industry leaders entrust core processes to Veeva is itself a market vote for a high degree of “missing it.”

  An honest ceiling is needed: indispensability does not mean irreplaceability in the sense of “institutional sole-source.” Its barrier is compliance know-how plus workflow embedding, not legal exclusivity or an exclusive license. Salesforce launched Life Sciences Cloud + Agentforce in September 2025 to compete head-on, showing that what customers “miss” is this class of compliance system, not necessarily only Veeva. So “customers would miss it a lot” is true, but “no one can replace it” is not. This separates Veeva from true bottleneck-type sole-source companies.

  Growth sustainability + not harming society/regulation: overall positive, with a direction of “helping compliance”. This is where Veeva is cleaner than many growth stocks. Its business model does not rely on regulatory arbitrage, harming users, or damaging the industry ecosystem. Instead, it turns “meeting FDA/EMA and other regulatory requirements” into product value; customers buy Veeva precisely to comply better. It does not have the fragility of “the business collapses once regulation tightens.” On the contrary, the stricter regulation becomes, the more mission-critical compliance software becomes. Growth comes from the slow variable of industry digitization penetration, not from an extractive or overdrawn playbook. The report judges that the industry has “long-term demand and regulation raises the importance of software,” and IQVIA public research says global medicine use and spending will continue growing through 2030, so the demand base is not shrinking.

  But one real tension must be marked: the privacy boundary of the data business. Veeva is building data products around Data Cloud, Crossix, and Compass (Patient/Prescriber/National) for patient journeys, prescriptions, target identification, and related use cases. The sustainability of these businesses naturally depends on compliant and ethical use of sensitive health data. A major data-compliance incident or tightening privacy regulation would create both reputational and growth risk. The report also lists a “major data compliance incident” as one of the signals that would overturn the thesis. This does not mean Veeva harms society; it means that the further its long-term growth moves into data/AI, the more dependent it becomes on not crossing data-use boundaries. This is the social/regulatory line it must hold for the long term.

  The Baillie Gifford-style conclusion: On the dual test of “how much customers would miss it if it disappeared tomorrow + whether growth avoids harming society and regulation,” Veeva performs well. It is operating infrastructure in a regulated industry (high missing-it factor and increasingly deeply embedded), and its growth model is positive, not extractive, aligned with regulation rather than in conflict with it. The one thing to watch continuously is the privacy-compliance boundary created by expansion in data/AI. Overall, this dimension is relatively strong: indispensability is real but not exclusive, and social/regulatory sustainability is good and healthy in direction.

  Jun 10, 2026
• QHow are the unit economics of this business (gross margin, incremental returns)? Do they improve or deteriorate with scale? Where does the earned cash go?8/10

  A

  The unit economics are excellent and improve with scale: subscription gross margin is 87%, operating leverage is being released again (operating margin back to 28.7%), and incremental returns are high. The cash earned is mainly kept on an extremely strong balance sheet (cash plus short-term investments of about $7.3 billion, almost no debt), with a small amount used for buybacks at poor timing and very little dependence on aggressive M&A for expansion. One discount is necessary: high stock-based compensation makes reported free cash flow look better than true distributable cash.

  Gross margin structure: the software layer is the true value core. FY2026 subscription gross margin was 87%, professional services gross margin was only 18%, and total gross margin was 76% (under the report’s framing). These numbers show that Veeva’s economic engine is software and data (87% gross margin and scalable), while professional services merely support implementation and expansion (18% gross margin, almost a companion runner). The high subscription mix also means revenue quality is good: FY2026 subscription revenue of $2.684 billion accounted for the vast majority of total revenue of $3.195 billion, is recognized ratably over contract terms, and is highly recurring.

  Do economics improve or deteriorate with scale? Clearly improve, and this has gone through one round of validation. Look at the operating margin trajectory (under the report’s framing): FY2021 25.8% → FY2022 27.3% → (investment and timing drag) FY2023 21.3%, FY2024 18.2% → (leverage released again) FY2025 25.2% → FY2026 28.7%. This “down first, then rebound to a new high” curve proves precisely that Veeva is not becoming less profitable as it grows. Investments depressed margins in the middle, and after scale and product maturity improved, profitability leverage reappeared. In FY2027 Q1 (as of 2026-04-30), non-GAAP operating income was $395.4 million, about 45% of revenue, giving a more direct view of the incremental profitability of the software model. The essence of high incremental returns is that an additional subscription carries little proportional marginal cost, so scale amortization lets more profit fall through from each additional dollar of revenue.

  Cash conversion: strong, but SBC requires a discount. FY2026 operating cash flow was $1.415 billion and net income was $909 million; OCF was materially above net income. Deferred revenue rose from $617 million in FY2021 to $1.489 billion in FY2026 (under the report’s framing), so customer prepayments genuinely support cash conversion. But a discount is immediately required: FY2026 stock-based compensation was $473 million, about 14.8% of revenue (under the report’s framing). The report therefore uses two layers: reported FCF of about $1.386 billion, and “conservative Owner Earnings” of about $913 million after treating SBC as a real economic cost. I agree that the latter is closer to “how much cash can be distributed without continuously diluting shareholders.” In other words, the unit economics are genuinely excellent, but the per-share picture is not as perfect as the statements suggest; ending shares were diluted by about 7.7% over five years.

  Where does the earned cash go? Three destinations:

  • The vast majority is retained as a net-cash fortress. As of FY2027 Q1, cash of $1.897 billion + short-term investments of $5.416 billion ≈ $7.31 billion, with almost no interest-bearing debt and shareholder equity of $7.304 billion. This is a balance sheet that is “not short of money and able to absorb pressure,” but it also means a large amount of excess cash earns relatively low returns (reducing the explanatory power of headline ROIC, which is why the report qualitatively describes ROIC as “extremely high and excellent” rather than giving pseudo-precise numbers).
  • Small buybacks with poor timing. FY2026 buybacks were done at an average price of $224.43, and in FY2027 Q1 the company spent another $221 million to repurchase about 1.3 million shares, while the current price is about $167.68 (2026-06-09). Buybacks are more about offsetting SBC dilution than creating value at low prices, and discipline is not outstanding.
  • Small and restrained M&A. The March 2026 acquisition of Ostro added AI capability, but historically Veeva has not relied on large, aggressive acquisitions to build scale. The report’s assessment of capital allocation is “rational but imperfect.”

  The Baillie Gifford-style conclusion: On the hard Baillie Gifford measure of “unit economics and incremental returns,” Veeva is an excellent student: 87% subscription gross margin, operating leverage re-released after validation, high incremental margins, and a business that improves rather than deteriorates with scale, clearly better than pseudo-growth companies whose gross margins fall as scale rises. The two deductions are “high SBC requires a discount to reported cash flow” and “excess cash + high-priced buybacks lower marginal capital returns.” Overall, this dimension is strong, but the need to discount reported FCF for SBC is unavoidable in an honest assessment.

  Jun 10, 2026
• QWhat conditions must all hold for it to rise fivefold in ten years? Are these conditions realistic? What expectations are embedded in today’s share price?3/10

  A

  For Veeva to rise fivefold in ten years (from about $168 to about $840, and market value from about $27.2 billion to about $136.0 billion), a set of optimistic conditions must hold at the same time. Fundamentals and valuation cannot rely on only one side. These conditions are not fantasy, but collectively they are tight and require stretching. Today’s share price already embeds “stable high-quality growth + broadly smooth Vault CRM migration,” so a lot of good news is already in the price and the margin of safety for blue-sky outcomes is not thick.

  First, fix the price anchor. The current share price is about $167.68 (2026-06-09 close), market value about $27.2 billion, P/E about 29.7x, and about 162.4 million shares. A fivefold rise in ten years implies a share price of about $840 and market value of about $136.0 billion.

  Conditions that must hold simultaneously for a fivefold rise in ten years (the Baillie Gifford focus is on years 3–10, but each condition needs a reality check):

  1. Revenue grows about 4–5x over ten years. Starting from FY2027 guidance of about $3.64 billion, revenue would need to reach about $14.5–$18.0 billion in ten years, requiring roughly 15% annual compound growth without deceleration for a decade. This requires continued penetration of R&D/Quality Cloud plus real scaling of AI/data monetization. The difficulty is that FY2027 Q1 subscription growth has already fallen to 15%, and sustaining 15% for ten years on a larger base is not easy. This is the most demanding condition.

  2. Margins are maintained or expand to a ~30%+ operating margin, and growth is not bought through dilutive economics. FY2026 operating margin has already recovered to 28.7%, and FY2027 Q1 non-GAAP operating margin was about 45%. The base is good, so this condition is relatively achievable, but SBC as a percentage of revenue must gradually decline and the company cannot keep beautifying results through dilution.

  3. The AI agent second curve truly converts into revenue. Ostro, Vault AI, and Veeva Falcon (FY2027 Q1: 50+ brands, all-application rollout in August, early adoption in November) could upgrade monetization from “selling seats” to “selling agentic labor/usage.” This is the key accelerator that can turn sustaining 15% for ten years from “hard” into “feasible,” but today it is still early adoption, an option rather than a realized fact.

  4. Vault CRM migration does not break, and share is retained. Management’s target of retaining at least 70% biopharma CRM share by 2030 must be achieved; otherwise, a collapse in the commercial segment would drag down overall growth (the report marks this as forward-looking, not validated).

  5. Valuation multiples do not contract materially. This is the most hidden condition: if the market still assigns about 30x PE ten years from now, then a fivefold share price requires net income to rise about fivefold; if the multiple falls back to ordinary software at 18–22x, net income must grow about 7–8x, a much steeper hurdle. In other words, a fivefold outcome requires either “profit up fivefold + valuation unchanged,” or “profit up more + valuation contraction.” The former is already optimistic; the latter is harder.

  Are these conditions realistic? Each condition on its own is not absurd, but simultaneous realization stacks optimism on optimism: 15% growth sustained for ten years + successful AI monetization + no major loss in CRM migration + no valuation compression. The report’s optimistic scenario (Owner Earnings growth of 12% for the first five years and 6% for the next five years) only produces intrinsic value of about $195–$215 per share, still far from the blue-sky required for a ten-year fivefold return. So I view “fivefold in ten years” as a possible but stretching upside scenario, not the base expectation. Baillie Gifford would acknowledge the upside imagination, but would not pretend it is highly probable.

  What expectations are embedded in today’s share price? At about 29.7x PE, and a forward PE of about 18.5x on FY2027 guided non-GAAP EPS of about $9.05 (167.68 / 9.05), with market value including about $7.3 billion of net cash (the operating-business multiple after deducting cash is higher), the pricing embeds that “the market is willing to treat Veeva for the long term as a stable, high-growth, high-quality vertical SaaS company, and that Vault CRM migration will be broadly smooth.” The report highlights that the most fragile assumption in the valuation is exactly this: if growth falls to mid-single digits, margins retreat, or the market reprices it from “high-quality SaaS” to “mature life sciences IT,” returns will be clearly pressured, and even a 40%–60% permanent drawdown is not unimaginable. In other words, today’s price already pays a meaningful premium for a “good company” and does not leave a thick margin of safety for blue-sky outcomes.

  The Baillie Gifford-style conclusion: Veeva has the business quality for a ten-year run (which is exactly what LTGG values), but a ten-year fivefold result requires a chain of optimistic conditions to light up at the same time, and today’s roughly $168 price already embeds “stable high-quality growth,” leaving insufficient discount for upside imagination. The honest judgment: the upside story is real, but it is a fivefold case that needs multiple optimistic forces to resonate plus a purchase price that is not cheap, not a fivefold outcome that arrives naturally from fundamentals. Buying more cheaply (the report’s ideal range of $125–$140) would materially improve the odds.

  Jun 10, 2026
• QWhy has the market not realized all this yet? Is it unable to understand it, looking down on it, or not looking far enough? What will become the “narrative inflection point”?3/10

  A

  For Veeva, this question needs to be answered honestly in reverse: the market actually understands it and does not look down on it. Veeva is not an overlooked, unfairly punished, underpriced hidden gem. Its roughly 40% pullback from the high over the past year is not “the market failing to recognize value,” but “the market removing part of the extreme premium it previously assigned and recalibrating expectations around Vault CRM migration and slowing growth.” If there is any perception gap, it is more about “not looking far enough”: the market may be underestimating the long-term monetization of the AI agent second curve. The real narrative inflection point is when AI moves from “story” to “quantifiable revenue and share.”

  First, reject the premise of “undervaluation”. The Baillie Gifford question “why has the market not realized it yet” assumes the target is undervalued, but Veeva’s report rating is “Watch,” explicitly judging that “the current price is not cheap enough and the margin of safety is insufficient.” Facts support this: at about $167.68 and a P/E of about 29.7x, Veeva still enjoys a clear premium versus its strongest comparable IQVIA (about 20x PE, with 2025 full-year revenue of $16.31 billion, adjusted EBITDA of $3.788 billion, FCF of $2.051 billion, net debt of $13.74 billion, and net leverage of 3.63x). This is a stock the market understands well and awards a quality premium to, not an ignored bargain. Coverage is also ample: 22 analysts cover it, and the average price target is about $248 (see Yahoo Finance VEEV), indicating it is heavily researched and does not sit in a “too hard to understand” valuation pocket.

  So what is the roughly 40% pullback? It is “valuation normalization,” not “market error.” The large share-price decline over the past year essentially reflects the market squeezing out the extreme premium Veeva received during the SaaS enthusiasm around 2021, while demanding a higher risk premium for two things: natural growth deceleration (FY2027 subscription growth down to 15%) and execution risk in the Vault CRM migration (legacy version expiring on 2029-12-31, Salesforce becoming a competitor). In other words, the market is not “failing to recognize value”; it is “taking back prior excessive optimism.” This is exactly the bear logic the report must face seriously: “the fattest dividend phase may have passed + high FCF is flattered by SBC + valuation is not cheap.”

  If one must identify a perception gap, it is more “not looking far enough” than “not understanding / looking down on it”:

  • Not “unable to understand”: the business model is simple, disclosure is transparent, coverage is ample, and institutions understand its compliance moat, subscription economics, and net-cash fortress well.
  • Not “looking down on it”: a near 30x PE and premium versus IQVIA precisely show that the market gives it above-peer respect.
  • The possible “not looking far enough” point: the market is still in a “believes but is not willing to price it fully” phase for the AI agent second curve (Ostro 50+ brands, Vault AI rolled out across all applications in August, Veeva Falcon early adoption in November; see FY2027 Q1). Because it is still in trial, and competition is stronger (Salesforce Agentforce competes head-on), the market rationally refuses to pay in advance for monetization that has not yet been delivered. This is the only place where Veeva may have a time-gap perception gap, but it is “an option not yet priced,” not “value buried.”

  What will become the narrative inflection point? (Completing the implicit premise.) The inflection point will not come from “the market suddenly understanding a business it already understands.” It will come from “uncertainty being removed by facts / a new curve being lit up by facts,” with four main candidates:

  1. AI turns from story into revenue: Veeva AI / Falcon / Ostro discloses quantifiable subscription increments or usage-based billing, proving that “selling agentic labor” can truly expand TAM. This is the strongest upward inflection point.
  2. The Vault CRM migration gate closes: migration completion continues to beat expectations, top 20 biopharma commitments move from 10 toward about 14, and share retention stays at “70%+,” removing the largest execution risk from the valuation. This would be an upward repricing catalyst.
  3. Growth reaccelerates or proves resilient: if revenue growth returns above 15% and holds with AI support, the market will raise long-term growth assumptions again.
  4. The downside inflection point must also be listed: if SBC stays high for a long time and the share count keeps expanding, or if migration produces obvious customer loss, the market will push Veeva further from “high-quality SaaS” toward a “mature life sciences IT” valuation. This is the permanent-loss scenario the report names (40%–60% drawdown).

  The honest Baillie Gifford-style conclusion: Veeva does not fit the image of an overlooked growth stock the market fails to understand or looks down on. It is well understood and receives a quality premium; the past year’s decline was valuation normalization, not a wrongful selloff. Its only potential perception gap is that the market has not yet priced the AI agent second curve, but that is a rational “pay after proof,” not undervaluation. The narrative inflection point depends on AI monetization and Vault CRM migration proving themselves with facts. Until then, it is better suited for “watch and wait for better odds” than for betting on a perception gap that does not really exist.

  Jun 10, 2026